The FDA has approved Egrifta WR, a concentrated formulation (F8) of tesamorelin, for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

Theratechnologies (THTX) announced that the FDA has approved the Company’s supplemental Biologics License Application, or sBLA, for the F8 ...

The new formula will replace EGRIFTA SV and treat excess visceral abdominal fat in adults with HIV and Lipodystrophy.

EGRIFTA WR™ will be supplied as four single-patient-use vials, each containing 11.6 mg of tesamorelin, sufficient for seven doses. The daily dose is 1.28 mg (0.16 mL of the reconstituted ...

with each vial containing enough tesamorelin for seven doses. The daily dose is 1.28 mg, injected subcutaneously, and can be stored at room temperature both before and after reconstitution.

EGRIFTA WR™ estará disponible en paquetes de cuatro viales de uso para un solo paciente, con cada vial conteniendo suficiente tesamorelin para siete dosis. La dosis diaria es de 1,28 mg ...

Each single-patient-use vial of Egrifta WR contains tesamorelin 11.6mg (equivalent to approximately 11.9mg of tesamorelin acetate); 1 reconstituted Egrifta WR vial provides daily doses for 7 ...

EGRIFTA WR™ will be supplied as four single-patient-use vials, each containing 11.6 mg of tesamorelin, sufficient for seven doses. The daily dose is 1.28 mg (0.16 mL of the reconstituted solution) ...

EGRIFTA WR™ will be available in packages of four single-patient-use vials, with each vial containing enough tesamorelin for seven doses. The daily dose is 1.28 mg, injected subcutaneously, and can be ...

MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage ...